K-V Pharma (KV-A) to Divest Generics Business in $60M Deal

K-V Pharmaceutical Co. (NYSE: KV-A)(NYSE: KV-B) reports that it has entered into a definitive agreement to divest Nesher Pharmaceuticals, Inc., its generics subsidiary, and the Company's generic business and assets to Zydus Pharmaceuticals (USA), Inc. for approximately $60 million in cash.

Closing is expected in Q212.

Jefferies & Company, Inc. acted as exclusive financial advisor to K-V in this transaction.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Real and RE/MAX Holdings receive court approval for merger
• Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
• Kimbell Royalty closes $221.2M mineral rights acquisition